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Background: Long-term noninvasive positive pressure ventilation (NPPV) is associated with an
excellent survival rate, especially in post-tuberculosis patients. Nothing is currently known on
which method of ventilatory support is associated with a better continuation of long-term
NPPV, which itself might lead to longer survival.
Methods: One hundred and eighty four post-tuberculosis patients, who started NPPV at the
Kyoto University Hospital group and the National Tokyo Hospital from June 1990 to August
2007, were examined retrospectively. Ventilator mode (an assisted mode or a pure controlled
mode) and potential confounders were examined with the discontinuation of NPPV as the
primary outcome.
Results: Patients treated with a pure controlled mode had significantly better continuation
rates (hazard ratio, 3.09; 95% confidential interval, 1.75e5.47; pZ 0.0001) and better survival
rates (Log-rank test; pZ 0.0031) than those treated with an assisted mode. Female gender and
no pulmonary lesions were also associated with a significantly better probability of continuing
NPPV. The five- and ten-year probabilities of continuing NPPV for 106 patients with a pure
controlled mode were 68.3% and 41.4%, respectively, while those for 76 patients with an as-
sisted mode were 46.7% and 12.7%, respectively.5 751 3852; fax: þ81 75 751 3854.
yoto-u.ac.jp (T. Tsuboi).
9 Elsevier Ltd. All rights reserved.
Ventilator mode in long-term NPPV 1855Conclusions: Patients treated with pure controlled ventilation had significantly better contin-
uation rates and survival rates than those treated with assisted ventilation. Prospective
randomized controlled trials are needed to verify the effectiveness of a pure controlled mode
in patients with not only restrictive thoracic disease but also other diseases including chronic
obstructive pulmonary disease.
ª 2009 Elsevier Ltd. All rights reserved.Introduction
Noninvasive positive pressure ventilation (NPPV) has been
widely used in the treatment of patients with chronic
hypercapnic respiratory failure.1e6 Recently, better
survival has been reported for post-tuberculosis patients
treated with home mechanical ventilation (HMV) than with
long-term oxygen therapy (LTOT) alone.7
In chest wall disorders, either pressure or volume preset
ventilation is known to be effective.8,9 Ventilation trig-
gered by the patient’s breath (an assisted mode) is thought
to be preferable to pure controlled ventilation.1,10
However, this choice of ventilator mode is not based on any
clinical evidence.
During NPPV, ventilator settings are commonly adjusted
in order to achieve better synchrony between the patients
and the ventilator. Most bilevel positive airway pressure
(PAP) devices have sensitive triggers that enhance
synchrony. However, when triggers have difficulty in
sensing a patient’s inspiration in the face of unexpected
leaks, end-expiratory lung hyperinflation, upper airway
obstruction, and/or an extremely weak respiratory effort or
output on the part of the patient, the efficacy of ventila-
tory assistance can become seriously compromised.11 The
setting of the expiratory trigger is also important. In
patients with obstructive ventilatory defects, setting the
expiratory trigger at a higher percentage of peak inspira-
tory flow has been reported to improve patienteventilator
synchrony and to reduce inspiratory muscle effort.12
On the other hand, a pure controlled mode could
accomplish truly passive ventilation9,13e19 and has been
described as the treatment of choice in patients with more
advanced respiratory disorders.17 Recently, controlled
NPPV using a timed (T) mode in bilevel PAP devices has
been demonstrated as feasible in patients with hypercapnic
chronic obstructive pulmonary disease (COPD).18 However,
another recent report of patients with chronic respiratory
failure showed no significant differences between an
assisted mode and a pure controlled mode with volumetric
ventilators, in a relatively short-term evaluation.19 There-
fore, we wanted to clarify the most suitable mode for long-
term NPPV in post-tuberculosis patients.
We hypothesized that patients receiving NPPV with
a pure controlled mode would have better continuation and
survival than those receiving NPPV with an assisted mode.
The effect of the two modes was retrospectively examined.
Methods
Patients
All post-tuberculosis patients who had started NPPV at the
Kyoto University Hospital group (six hospitals) and theNational Tokyo Hospital over the period from June 15, 1990
to August 2, 2007, were included in this retrospective study.
All patients had suffered from chronic hypercapnic venti-
latory disorders. Patients started on NPPV therapy either
after an acute episode or at a chronic state. The decision
for initiation of NPPV was based on clinical symptoms such
as morning headache, persistent daytime hypercapnia
(PaCO2> 6.0 kPa) and/or nocturnal hypoventilation, and
clinical instability with recurrent hospitalizations. Patients
with other causes of chronic respiratory failure, such as
idiopathic kyphoscoliosis (KS), neuromuscular disorders or
COPD were excluded. The patients were followed up until
November 30, 2007. Clinical surveys had been performed at
the end of every year from 1995 to 2002, in December 2004
and in December 2007.
Measurements
Age at the start of NPPV, gender, body-mass index (BMI),
vital capacity (percentage of predicted), forced expiratory
volume in 1 s over forced vital capacity (FEV1/FVC), pres-
ence of pulmonary lesions, duration of LTOT before start of
NPPV, hospitalization rate due to acute episodes per year
before start of NPPV, status on introduction of NPPV (i.e.,
acute or chronic state), the institution where NPPV was
introduced (the Kyoto University Hospital group or the
National Tokyo Hospital), type of ventilator at the start of
long-term NPPV (pressure or volume preset ventilator),
concurrent use of LTOT after the start of NPPV and venti-
lator mode (an assisted mode or a pure controlled mode),
were all examined and/or documented for risk factors.
Arterial blood gases were measured during spontaneous
breathing with prescribed supplemental oxygen before and
three months after the start of long-term NPPV.
All data and information on the clinical course of each
patient were collected from outpatient and inpatient clin-
ical records.
Clinical protocol for introducing long-term NPPV
Patients who started NPPV at a chronic state were carefully
instructed in the use of the ventilator and in the way of
fitting the mask during daytime. Most patients learnt how to
handle the NPPV devices within the first week. After this
was achieved, patients started to receive NPPV nocturnally,
and most were able to receive NPPV throughout the night
within a week. Patients were discharged from hospital only
after they were comfortable with NPPV, were able to
tolerate nocturnal NPPV, and were confident of dealing
with the NPPV devices.
For patients who started NPPV at an acute state, the
need to continue NPPV was estimated carefully after they
had recovered thoroughly from their acute episode.
1856 T. Tsuboi et al.Criteria that had to be met in order to continue NPPV were:
(1) daytime PaCO2 without NPPV of more than 8.0 kPa and
(2) recurrence of symptoms resulting from nocturnal
hypoventilation a few days after discontinuation of NPPV. If
continuation of NPPV was judged to be clinically beneficial,
the training for long-term NPPV was started using the same
protocol as described above for chronic state patients.
Ventilators and humidifiers
Of the 26 patients starting NPPV with a volume preset
ventilator, 12 were ventilated with Acoma ARF 900E
(Acoma; Tokyo, Japan), 10 with PLV 100 (Lifecare; Denver,
CO), three with Bear 33 (Bear Medical Systems; Palm
Springs, CA) and one with Companion 2800 (Puritan-Ben-
nett; Middlesex, UK). Of the 158 patients starting NPPV with
a pressure preset ventilator, 133 were using the VPAP series
(VPAP, VPAP II ST, VPAP II ST-A and VPAP III ST-A; Resmed;
Sidney, Australia), 24 the BiPAP series (BiPAP S/T-D20,
BiPAP S/T-D30, BiPAP synchrony and BiPAP harmony;
Respironics; Murrysville, PA) and one the O’NYX (Pierre
Medical; Verrieres le Buisson, France). Heated humidifiers
were administered for all patients using bilevel PAP
devices. For patients using a volume preset ventilator,
a cold passover humidifier was applied first. If patients
experienced dryness of the mucosa, heated humidifiers
were provided.
Ventilator selection and ventilator settings
At the start of NPPV, volume preset ventilators were
utilized with custom fabricated nasal masks20 or commer-
cially available interfaces. Pressure preset ventilators using
bilevel PAP devices were applied with commercially avail-
able interfaces.
In our institutes, both an assisted mode and a pure
controlled mode had regularly been tested for all patients
who started long-term NPPV and the patient chose the
mode with which they felt more comfortable during the
first week. Every physician followed this procedure and his
or her preference was not concerned in the selection of
ventilator mode. From our clinical experience, the most
common reason for the selection of an assisted mode was
‘‘asynchrony between the ventilator and patients’ own
breathing in a pure controlled mode, due to difficulty in
ceasing their breathing effort’’, while the most common
reason for preferring a pure controlled mode was ‘‘more
resting sensation’’.
Assisted ventilation was introduced as follows. In the
pressure targeted ventilators, inspiratory positive airway
pressure (IPAP), expiratory positive airway pressure (EPAP),
and a backup breathing frequency (fR) were delivered in
a spontaneous timed (ST) mode. In the volume targeted
ventilators, tidal volume (VT), positive end-expiratory
pressure (PEEP), a backup fR and an inspiratory flow rate
were provided in an assist controlled (A/C) mode or
a synchronized intermittent mandatory ventilation (SIMV)
mode. IPAP or VT was adjusted by increasing step-by-step to
the level of patients’ tolerance. EPAP or PEEP was set as
low as possible for easy expiration, while, in patients with
concomitant obstructive ventilatory disorders and/or upperairway obstruction, EPAP or PEEP was increased to improve
inspiratory triggering. A backup fR was set approximately
four to five breaths below the spontaneous breathing rate
without NPPV. The inspiratory flow rate in the volume tar-
geted ventilators was regulated so that the duty cycle ratio
(fraction of inspiration to the total duration of respiratory
cycle: TI/Ttot) was around 45%.
Pure controlled ventilation was introduced as follows. In
the pressure targeted ventilators, a fixed IPAP, a fixed EPAP,
a fixed fR, and a fixed inspiratory time were delivered in a T
mode. In the volume targeted ventilators, a fixed VT, a fixed
fR, and a fixed inspiratory flow rate were provided in
a controlled mode. In the pure controlled mode, patients
were instructed to be relaxed, cease their own breathing
effort, and surrender themselves to the ventilator
completely. NPPV was titrated to achieve passive ventila-
tion by gradually increasing VT or support pressure to the
level of the patients’ tolerance. The fR was set slightly
higher than the rate of a patient’s own spontaneous
breathing in order to suppress his or her respiratory effort.
TI/Ttot was set to between 40% and 50%.
Supplemental oxygen was added to NPPV in order to
maintain an arterial oxygen saturation >95% while
receiving diurnal NPPV and >90% while receiving nocturnal
NPPV.
Of the six patients who changed from a volume preset to
pressure preset ventilator several years after the start of
long-term NPPV, only one changed the ventilator mode
(from a pure controlled mode to an assisted mode) based on
personal preference. For purposes of the analyses, this
female patient was classified in the pure controlled mode
group because of the longer duration of NPPV use in this
mode. Of the patients using bilevel PAP devices, two
changed the ventilator mode from an ST mode to a T mode
because of limited control of their respiratory failure with
an ST mode. One of the patients was classified in the pure
controlled mode group and the other in the assisted mode
group.
This study was approved by the Ethics Committee of
Kyoto University and individual consent was not obtained as
stipulated by the Committee, in a direction of which, the
protocol of this study is opened on the website of our
institute and any inquiries from all concerned will be
answered.Statistical analysis
Means and standard deviations are reported for patients’
baseline characteristics and ventilator settings. Unpaired t
test and the Pearson c2 statistic were used to compare
differences in baseline characteristics and ventilator
settings between the assisted mode and pure controlled
mode. Univariate and multivariate comparisons of contin-
uation rates of long-term NPPV by risk factors in 182
patients, by risk factors including PaCO2 before the start of
long-term NPPV and improvement of PaCO2 after three
months of NPPV treatment in 103 patients starting NPPV at
a chronic state, and by risk factors including ventilator
settings such as IPAP, EPAP, support pressure and fR in 156
patients using bilevel PAP devices, were performed using
Cox proportional hazards regression analysis. Between the
Ventilator mode in long-term NPPV 1857two ventilator modes, comparison of continuation rates of
long-term NPPV in 182 patients, and comparison of survival
rates both in 182 patients including 15 patients who
switched to long-term tracheostomy positive pressure
ventilation (TPPV) after long-term NPPV, and in 167
patients excluding those 15 patients, were assessed using
KaplaneMeier analyses (Log-rank test).Results
Patient characteristics
A total of 184 patients who continued NPPV for more than
two months were available for follow-up. Of these, 170 had
intra-pulmonary lesions with chest wall deformities, and 14
had Pott disease without pulmonary lesions. Two patients
discontinued NPPV due to improvement in hypercapnic
respiratory failure, 21 and 36 months after the start of long-
term NPPV, respectively. Therefore, further analyses wereTable 1 Patient baseline characteristics (nZ 182).
Ventilator mode Total (nZ 182)
Age (years) 69.0 (8.4)
Gender
Female/male 85/97
BMI (kg/m2) 18.8 (3.6)
% Predicted VC (%) 32.9 (9.6)
FEV1/FVC (%) 72.5 (16.4)
Pulmonary lesions
þ/ 168/14
Annual hospitalization
rate due to acute episodes
before start of NPPV
1.41 (1.00)
Patients’ state
Acute/chronic 79/103
Institution
Kyoto/Tokyo 75/107
Type of ventilator
Volume/pressure 26/156
Duration of LTOT before start of
NPPV (years)
5.13 (4.71)
Use of LTOT after start of NPPV
þ/ 169/13
ABGAs (start of NPPV at acute state) nZ 79
pH 7.32 (0.06)
PaO2 (kPa) 8.6 (2.6)
PaCO2 (kPa) 11.3 (2.6)
HCO3
 (mmol/l) 42.4 (6.0)
ABGAs (start of NPPV at chronic state) nZ 103
pH 7.35 (0.04)
PaO2 (kPa) 10.4 (2.3)
PaCO2 (kPa) 9.7 (1.9)
HCO3
 (mmol/l) 39.0 (6.1)
Values given as mean (standard deviation).
BMI, body-mass index; VC, vital capacity; FEV1, forced expiratory vol
pressure ventilation; LTOT, long-term oxygen therapy; ABGAs, arter
dioxide tensions, respectively; HCO3
, bicarbonate.undertaken in 182 patients, and their characteristics are
presented in Table 1.
Overall, the group was characterized by severe restric-
tive ventilatory failure, severe hypercapnia, moderate
malnutrition and unstable clinical conditions. At baseline,
the incidence of pulmonary lesions was higher, and the
duration of LTOT before the start of NPPV was longer, in the
pure controlled mode group. There was no statistical
difference between the two ventilator modes, with respect
to other risk factors. Among the 103 patients who started
NPPV in a chronic state, patients in the pure controlled
mode group were more acidotic and more hypercapnic than
those in the assisted mode group.
Overall outcome
The overall outcome of the 184 post-tuberculosis patients is
presented in Fig. 1. The two patients, described above,
who withdrew the use of NPPV due to improvement, are
included in this flow diagram. The outcome of theAssisted (nZ 76) Pure controlled (nZ 106) p value
68.5 (9.4) 69.4 (7.6) 0.48
38/38 47/59 0.45
19.5 (4.1) 18.4 (3.1) 0.052
33.7 (9.69) 32.0 (8.8) 0.26
72.5 (17.5) 72.5 (15.7) 1.00
66/10 102/4 0.019
1.46 (1.03) 1.37 (0.98) 0.54
33/43 46/60 1.00
36/40 39/67 0.15
10/66 16/90 0.71
3.84 (4.29) 6.05 (4.80) 0.0017
68/8 101/5 0.13
nZ 33 nZ 46
7.33 (0.06) 7.31 (0.05) 0.092
8.7 (2.2) 8.6 (2.9) 0.84
10.7 (3.1) 11.7 (2.2) 0.083
41.2 (6.3) 43.1 (5.8) 0.190
nZ 43 nZ 60
7.36 (0.03) 7.34 (0.04) 0.0033
10.2 (2.5) 10.6 (2.1) 0.38
9.1 (1.7) 10.1 (2.0) 0.01
38.0 (5.6) 39.7 (6.4) 0.19
ume in 1 s; FVC, forced vital capacity; NPPV, noninvasive positive
ial blood gas analyses; PaO2, PaCO2, arterial oxygen and carbon
Post-ptuberculosis with a long-term NPPV
n = 184
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n = 77
Pure controlled mode
n = 107
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n = 8
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n = 2
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n = 1
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Figure 1 Overall outcome of 184 post-tuberculosis patients.
1858 T. Tsuboi et al.remaining 182 was as follows. Two patients temporarily
discontinued NPPV for several months and then restarted.
After the long-term use of NPPV, 15 patients switched to
long-term TPPV for a mean (SD) duration of 2.2 (2.3) years.
Ultimately, 85 patients died. Among the 40 non-survivors
treated with an assisted mode, 29 died from progression of
respiratory failure, five from malignancy, and six from other
causes. Among the 45 non-survivors treated with a pure
controlled mode, 32 died from progression of respiratoryTable 2 Ventilator settings (nZ 182).
Assisted
Volume preset ventilator nZ 10
Tidal volume (ml) 606 (11
Tidal volume (ml/kg) 15.8 (5.6
Respiratory rate (/min) 19.8 (4.0
Additional oxygen (l/min) 1.2 (0.8
Pressure preset ventilator (bilevel PAP devices) nZ 66
IPAP (cm H2O) 12.7 (3.7
EPAP (cm H2O) 3.7 (1.2
Respiratory rate (/min) 17.2 (4.1
TI/Ttot (%) e
Additional oxygen (l/min) 1.6 (1.1
Values given as mean (standard deviation).
PAP, positive airway pressure; IPAP, set inspiratory positive airway pres
time; Ttot, total respiratory time.failure, seven from malignancy, and six from other causes.
In December 2007, NPPV was being continued in 95
patients, with a mean (SD) duration of 5.0 (3.6) years.A comparison between the two ventilator modes
A comparison between different ventilator modes is also
shown in Table 2. In volume preset ventilators, VT was(nZ 76) Pure controlled (nZ 106) p value
nZ 16
4) 513 (101) 0.041
) 12.2 (4.0) 0.14
) 26.2 (3.6) 0.30
) 1.5 (1.1) 0.37
nZ 90
) 16.5 (3.1) <0.0001
) 3.9 (1.0) 0.49
) 23.0 (2.7) <0.0001
40.8 (3.1) e
) 1.6 (0.9) 0.92
sure; EPAP, set expiratory positive airway pressure; TI, inspiratory
0 2 4 6 8 10 12 14
0.0
0.4
0.2
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Figure 2 KaplaneMeier curves (with results of Log-rank test)
of continuation rates of long-term noninvasive positive pres-
sure ventilation: comparison of patients using the pure
controlled mode with those using an assisted mode.
Ventilator mode in long-term NPPV 1859slightly larger in the assisted mode, while in the bilevel PAP
devices, IPAP and fR were higher in the pure controlled
mode (T mode).
In 103 patients beginning NPPV in a chronic state, for
three months after initiation of long-term NPPV, daytime
PaCO2 measured during spontaneous breathing decreased
in the pure controlled mode group by 2.3 (1.5) kPa, from
10.2 (1.9) kPa to 7.8 (1.1) kPa; this was greater than in the
assisted mode group which decreased by 1.2 (1.0) kPa, from
9.1 (1.6) kPa to 7.9 (1.4) kPa (pZ 0.0003). In the univariate
Cox proportional hazards models, a pure controlled mode,
no parenchymal pulmonary lesions, female gender and
a higher BMI were all significantly associated with higher
continuation rates of long-term NPPV, while the other risk
factors were not associated.
In multivariate Cox proportional hazards models, a pure
controlled mode, female gender and no pulmonary lesions
were all significantly associated with higher continuation
rates of long-term NPPV (Table 3), while the other risk
factors were not associated.
PaCO2 before the start of long-term NPPV, and the
improvement of PaCO2 after three months of NPPV treat-
ment, in 103 patients beginning NPPV in a chronic state,
and IPAP, EPAP, support pressure and fR in 158 patients
using bilevel PAP devices, were not significantly associated
with higher continuation rates of long-term NPPV in
univariate and multivariate analyses.
Results of the KaplaneMeier analysis showed significant
increased continuation rates of long-term NPPV among the
pure controlled group (Fig. 2). The five- and ten-year
probabilities of continuing NPPV for all 182 patients were
60.0% and 31.0%, respectively. The corresponding proba-
bilities for 106 patients with the pure controlled mode were
68.3% and 41.4%, respectively while those for 76 patients
with the assisted mode were 46.7% and 12.7%, respectively.
Survival rates for patients in the pure controlled mode
groupwere better than those in the assistedmode group, not
only in the total population of 182 patients (Log-rank test;
pZ 0.0031), but also in the sub-population of 167 patients
that excluded the 15 patients who switched to long-term
TPPV after long-term NPPV (Log-rank test; pZ 0.0074).Discussion
In the present study of 182 post-tuberculosis patients
receiving long-term NPPV, we first found that patientsTable 3 Multivariate modality model (nZ 182).
Variable n Hazard ratio (95%CI) p value
Ventilator mode
Assisted 76 3.10 (1.75e5.47) 0.0001
Pure controlled 107 Reference
Pulmonary lesions
þ 168 9.63 (2.39e38.88) 0.0015
 14 Reference
Gender
Female 85 Reference
Male 97 1.91 (1.05e3.47) 0.035
CI, confidence interval.treated with a pure controlled mode had significantly
better continuation rates and longer survival rates than
those treated with an assisted mode. The ten-year proba-
bility of continuing NPPV in the pure controlled mode was
approximately three-fold higher than that in the assisted
mode. Female gender and no pulmonary lesions were also
both associated with a significantly better probability of
continuing NPPV.
Recently, a Swedish study showed that, in post-tuber-
culosis patients, HMV in which most patients were treated
with NPPV was associated with a better survival outcome
than LTOT alone.7 The five- and ten-year survival rates in
this Swedish study were approximately 50% and 10%,
respectively, which are very similar to the rates reported in
our study for patients with the assisted mode.
While most physicians seem to use an assisted mode,10,17
a few use the pure controlled mode or equivalent
controlled ventilation in long-term NPPV for patients with
RTD15e17,19 and also for those with COPD.18,21,22 In general,
the pure controlled mode might be preferred in patients
with unreliable respiratory effort and massively overloaded
respiratory muscles.17 In the present study, of 184 patients
who started NPPV, 107 preferred the pure controlled
ventilation while 77 patients selected the assisted ventila-
tion; as shown in Table 1, the patients who selected pure
controlled ventilation had more progressive disorders at
baseline.
There have been several reports on the impact of
ventilation settings, including ventilator type (volume or
pressure preset ventilator), IPAP, EPAP, support pressure
and fR, on changes in physiological and functional param-
eters.8,9,14,16e19,21e23 In the ST mode, IPAP and support
pressure were reported to play an important role in the
improvement of blood gases and lung function in patients
with restrictive thoracic diseases (RTD); however, this was
a relatively short-term study.23 In the present study, IPAP,
EPAP, support pressure, fR, and the improvement of PaCO2
after three months of NPPV treatment were not signifi-
cantly associated with higher continuation rates of long-
term NPPV in univariate and multivariate analyses. There-
fore, we think there is a possibility that the ventilator
1860 T. Tsuboi et al.settings for inducing passive ventilation21,22 might be more
important than those aimed at maximally decreasing
PaCO2. These two ventilator settings might be quite similar
ones except the IPAP settings. Further studies are necessary
to compare the effect of the former with the latter venti-
lator settings, on changes in physiological and functional
parameters and on the continuation rate of long-term
NPPV.
In our study, pure controlled ventilation was used to
achieve passive ventilation leading to better unloading of
respiratory muscles. An assisted mode with a higher backup
fR might be equivalent to the pure controlled mode.
However, in awake humans, a high percentage of triggered
breaths during a maximum tolerated backup fR in an ST
mode has been observed, while nearly all breaths were
assisted during a backup fR of five breaths below
a maximum tolerated backup fR.24 In sleeping humans, to
our knowledge, an assisted mode with a higher backup fR in
NPPV has not been studied precisely using polysomnography
with recordings of transcutaneous carbon dioxide tension,
mask pressure, and esophageal pressure. Moreover, a study
comparing the pure controlled mode to an assisted mode
with an equivalent backup fR during nocturnal NPPV has
never been performed. In the assisted mode, triggered
breaths may occur in some part of the sleep period and
inspiratory time may fluctuate breath by breath according
to an algorithm of expiratory triggering. Therefore,
whether these two modes can induce the same regular
passive ventilation during sleep needs to be examined.
Pure controlled ventilation has recently been reported
to elicit disuse atrophy of the respiratory muscles.25,26
Although ventilator-induced muscle atrophy in a diaphragm
may occur in patients receiving full invasive ventilation,
this is not the same situation for long-term NPPV patients
receiving mainly nocturnal ventilatory support like our
patients. In fact, an improvement in respiratory muscle
strength after introduction of long-term NPPV using the
pure controlled mode has been reported.18
We recognize that there were several limitations of our
study. Firstly, the results need to be verified by prospective
randomized control trials. Secondly, we have not provided
validated and objective data on the physiological effects of
the ventilator mode on respiratory muscle rest. Thirdly, in
our study, patients’ preference was the most important
factor in the selection of ventilator mode at the start of
long-term NPPV. We could not however assign patients to
a ventilator mode which they could not easily learn to use
and thus accept, because the success of long-term NPPV
essentially depends on the patients’ acceptance and
compliance with mechanical ventilation.
In conclusion, we first found that post-tuberculosis
patients treated with NPPV using the pure controlled mode
had significantly better continuation and longer survival
than those using an assisted mode. Further prospective
trials are needed to ensure the effectiveness of the pure
controlled mode in patients with not only RTD but also
other diseases including COPD.Conflicts of interest
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